Tracked deals
3
3 tracked deals across 2022-2026.
Operating Company
Healthcare
United BioSource
King of Prussia, Pennsylvania, United States
United BioSource LLC (UBC) provides evidence development solutions for biopharma—uniting scientific expertise, data and analytics, and innovative technologies to generate real-world data for earlier, more informed decisions and improved patient outcomes.
- Focus Areas
- Real-World Evidence (RWE), HEOR / Health Economics, Evidence synthesis / HTA
- Website
- ubc.com
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Buyout
3 buyout
United BioSource Acquisition Volume by Year
Last 2 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
January 5, 2026
- Buyer
- United BioSource LLC (UBC)
- Target
- Evidinno Outcomes Research Inc. (Evidinno)
- Industry
- Healthcare Services
- Location
- British Columbia, Canada
- Type
- Buyout
United BioSource LLC (UBC) acquired Evidinno Outcomes Research Inc., a Vancouver-based healthcare research consulting firm specializing in real-world evidence (RWE), epidemiology, evidence synthesis, and health economics/HEOR. The acquisition will expand UBC’s evidence generation and late-stage/post-approval capabilities, with Evidinno operating as a wholly owned subsidiary.
-
July 28, 2022
- Buyer
- United BioSource LLC (UBC)
- Target
- Examoto, LLC
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Type
- Buyout
United BioSource (UBC) has acquired Examoto, LLC, a provider of FDA-mandated REMS compliance platforms and risk-mitigation technology for the pharmaceutical industry. The acquisition expands UBC's REMS capabilities by combining Examoto's technology-driven REMS platform with UBC's scientific, safety, and commercialization services; terms were not disclosed.
-
March 9, 2022
- Buyer
- United BioSource LLC (UBC)
- Target
- MarketShare Movers (MSM)
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Type
- Buyout
United BioSource LLC (UBC) has acquired MarketShare Movers (MSM), a data-driven prescription drug benefit and patient affordability company. The acquisition expands UBC's patient access and affordability capabilities by adding MSM's co-pay program execution, pharmacy adjudication, and proprietary analytics to UBC's patient access and commercialization services.
Related Acquisition Pages
Selling a company? Get in front of buyers like United BioSource
Turn tracked acquisition activity into an outreach-ready buyer list.